Importance of Phosphate Control for Restoration of Vascular Responsiveness in End‐Stage Renal Disease Patients Converted to Nocturnal Hemodialysis
Identifieur interne : 002883 ( Main/Exploration ); précédent : 002882; suivant : 002884Importance of Phosphate Control for Restoration of Vascular Responsiveness in End‐Stage Renal Disease Patients Converted to Nocturnal Hemodialysis
Auteurs : C. T. Chan [Canada] ; P. J. Harvey [Canada] ; A. Pierratos [Canada] ; J. A. Miller [Canada] ; J. S. Floras [Canada]Source :
- Hemodialysis International [ 1492-7535 ] ; 2004-01.
Abstract
Hyperphosphatemia and poor uremia control are established cardiovascular risk factors in patients with end‐stage renal disease (ESRD) associated with impaired endothelial dependent and independent vasodilation (EDV and EIV). Nocturnal hemodialysis [6 × 8 h/week] augments dialysis dose and offers normal phosphate (Pi) balance. We hypothesized that NHD would restore EDV (endothelial function) and EIV (vascular smooth muscle cell function) by simultaneously improving uremia and Pi control. 2 groups of ESRD patients (mean age 41 ± 2 years) stratified according to their baseline plasma Pi levels (normal Pi <1.8 mM, high Pi >1.8 mM) were studied. Dialysis dose (Kt/V per session), plasma Pi, blood pressure (BP) and brachial artery responses to reactive hyperemia (EDV), and sublingual nitroglycerin (EIV) were examined before, 1 and 2 months after conversion from conventional hemodialysis (CHD) [3 × 4 h/week] to NHD. After 2 months, NHD increased dialysis dose (from 1.24 ± 0.06 to 2.04 ± 0.08; p = 0.02) and lowered BP (from 140 ± 5/82 ± 3 to 119 ± 1/71 ± 3, p = 0.01) in all patients. In patients with adequate Pi control during CHD, EDV was normalized after 1 month of NHD. In contrast, in the high Pi group, 1 month of NHD was sufficient to reduce plasma phosphate levels, but 2 months of NHD was required for EDV to improve. Variables Normal Pi (n=10) CHD NHD (1month) NHD (2months) High Pi (n=8) CHD NHD (1month) NHD (2 months) Pi (mM) −1.44 ± 0.09 1.08 ± 0.07* 1.14 ± 0.11* 2.52 ± 0.3 1.40 ± 0.17* 1.26 ± 0.05* EDV (%) −3.4 ± 2.7 7.5 ± 1.9* 7.6 ± 1.3* −1.7 ± 1.3 0.37 ± 1.6† 8.8 ± 1.2* EIV (%) −8.2 ± 4.8 10.3 ± 2.0 15.1 ± 2.0* 5.1 ± 1.1 6.6 ± 0.8† 16.9 ± 1.7* * p < 0.05 from values during CHD. † p < 0.05 between the normal and high Pi groups. Correction of uremia without normalization of plasma Pi is insufficient to improve EDV. The time course over which this improvement in vascular responsiveness occurs is delayed in hyperphosphatemic patients, suggesting that improvement in endothelial and vascular smooth muscle cell function requires restoration of normal intracellular Pi balance.
Url:
DOI: 10.1111/j.1492-7535.2004.0085ag.x
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000906
- to stream Istex, to step Curation: 000900
- to stream Istex, to step Checkpoint: 001355
- to stream Main, to step Merge: 002892
- to stream Main, to step Curation: 002883
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Importance of Phosphate Control for Restoration of Vascular Responsiveness in End‐Stage Renal Disease Patients Converted to Nocturnal Hemodialysis</title><author><name sortKey="Chan, C T" sort="Chan, C T" uniqKey="Chan C" first="C. T." last="Chan">C. T. Chan</name></author><author><name sortKey="Harvey, P J" sort="Harvey, P J" uniqKey="Harvey P" first="P. J." last="Harvey">P. J. Harvey</name></author><author><name sortKey="Pierratos, A" sort="Pierratos, A" uniqKey="Pierratos A" first="A." last="Pierratos">A. Pierratos</name></author><author><name sortKey="Miller, J A" sort="Miller, J A" uniqKey="Miller J" first="J. A." last="Miller">J. A. Miller</name></author><author><name sortKey="Floras, J S" sort="Floras, J S" uniqKey="Floras J" first="J. S." last="Floras">J. S. Floras</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:EB703E2B69F4879EB300F1A65B1C6DB5A0A815A1</idno><date when="2004" year="2004">2004</date><idno type="doi">10.1111/j.1492-7535.2004.0085ag.x</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-RKGVX15H-Q/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000906</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000906</idno><idno type="wicri:Area/Istex/Curation">000900</idno><idno type="wicri:Area/Istex/Checkpoint">001355</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001355</idno><idno type="wicri:doubleKey">1492-7535:2004:Chan C:importance:of:phosphate</idno><idno type="wicri:Area/Main/Merge">002892</idno><idno type="wicri:Area/Main/Curation">002883</idno><idno type="wicri:Area/Main/Exploration">002883</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Importance of Phosphate Control for Restoration of Vascular Responsiveness in End‐Stage Renal Disease Patients Converted to Nocturnal Hemodialysis</title><author><name sortKey="Chan, C T" sort="Chan, C T" uniqKey="Chan C" first="C. T." last="Chan">C. T. Chan</name><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>University of Toronto, Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Harvey, P J" sort="Harvey, P J" uniqKey="Harvey P" first="P. J." last="Harvey">P. J. Harvey</name><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>University of Toronto, Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Pierratos, A" sort="Pierratos, A" uniqKey="Pierratos A" first="A." last="Pierratos">A. Pierratos</name><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>University of Toronto, Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Miller, J A" sort="Miller, J A" uniqKey="Miller J" first="J. A." last="Miller">J. A. Miller</name><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>University of Toronto, Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Floras, J S" sort="Floras, J S" uniqKey="Floras J" first="J. S." last="Floras">J. S. Floras</name><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>University of Toronto, Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Hemodialysis International</title><title level="j" type="alt">HEMODIALYSIS INTERNATIONAL</title><idno type="ISSN">1492-7535</idno><idno type="eISSN">1542-4758</idno><imprint><biblScope unit="vol">8</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="91">91</biblScope><biblScope unit="page" to="91">91</biblScope><biblScope unit="page-count">100</biblScope><publisher>Blackwell Science Inc</publisher><pubPlace>Oxford, UK; Malden, USA</pubPlace><date type="published" when="2004-01">2004-01</date></imprint><idno type="ISSN">1492-7535</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1492-7535</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Hyperphosphatemia and poor uremia control are established cardiovascular risk factors in patients with end‐stage renal disease (ESRD) associated with impaired endothelial dependent and independent vasodilation (EDV and EIV). Nocturnal hemodialysis [6 × 8 h/week] augments dialysis dose and offers normal phosphate (Pi) balance. We hypothesized that NHD would restore EDV (endothelial function) and EIV (vascular smooth muscle cell function) by simultaneously improving uremia and Pi control. 2 groups of ESRD patients (mean age 41 ± 2 years) stratified according to their baseline plasma Pi levels (normal Pi <1.8 mM, high Pi >1.8 mM) were studied. Dialysis dose (Kt/V per session), plasma Pi, blood pressure (BP) and brachial artery responses to reactive hyperemia (EDV), and sublingual nitroglycerin (EIV) were examined before, 1 and 2 months after conversion from conventional hemodialysis (CHD) [3 × 4 h/week] to NHD. After 2 months, NHD increased dialysis dose (from 1.24 ± 0.06 to 2.04 ± 0.08; p = 0.02) and lowered BP (from 140 ± 5/82 ± 3 to 119 ± 1/71 ± 3, p = 0.01) in all patients. In patients with adequate Pi control during CHD, EDV was normalized after 1 month of NHD. In contrast, in the high Pi group, 1 month of NHD was sufficient to reduce plasma phosphate levels, but 2 months of NHD was required for EDV to improve. Variables Normal Pi (n=10) CHD NHD (1month) NHD (2months) High Pi (n=8) CHD NHD (1month) NHD (2 months) Pi (mM) −1.44 ± 0.09 1.08 ± 0.07* 1.14 ± 0.11* 2.52 ± 0.3 1.40 ± 0.17* 1.26 ± 0.05* EDV (%) −3.4 ± 2.7 7.5 ± 1.9* 7.6 ± 1.3* −1.7 ± 1.3 0.37 ± 1.6† 8.8 ± 1.2* EIV (%) −8.2 ± 4.8 10.3 ± 2.0 15.1 ± 2.0* 5.1 ± 1.1 6.6 ± 0.8† 16.9 ± 1.7* * p < 0.05 from values during CHD. † p < 0.05 between the normal and high Pi groups. Correction of uremia without normalization of plasma Pi is insufficient to improve EDV. The time course over which this improvement in vascular responsiveness occurs is delayed in hyperphosphatemic patients, suggesting that improvement in endothelial and vascular smooth muscle cell function requires restoration of normal intracellular Pi balance.</div></front></TEI><affiliations><list><country><li>Canada</li></country><region><li>Ontario</li></region><settlement><li>Toronto</li></settlement><orgName><li>Université de Toronto</li></orgName></list><tree><country name="Canada"><region name="Ontario"><name sortKey="Chan, C T" sort="Chan, C T" uniqKey="Chan C" first="C. T." last="Chan">C. T. Chan</name></region><name sortKey="Floras, J S" sort="Floras, J S" uniqKey="Floras J" first="J. S." last="Floras">J. S. Floras</name><name sortKey="Harvey, P J" sort="Harvey, P J" uniqKey="Harvey P" first="P. J." last="Harvey">P. J. Harvey</name><name sortKey="Miller, J A" sort="Miller, J A" uniqKey="Miller J" first="J. A." last="Miller">J. A. Miller</name><name sortKey="Pierratos, A" sort="Pierratos, A" uniqKey="Pierratos A" first="A." last="Pierratos">A. Pierratos</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/StressCovidV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002883 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002883 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= StressCovidV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:EB703E2B69F4879EB300F1A65B1C6DB5A0A815A1
|texte= Importance of Phosphate Control for Restoration of Vascular Responsiveness in End‐Stage Renal Disease Patients Converted to Nocturnal Hemodialysis
}}
| This area was generated with Dilib version V0.6.33. |  |